Angiogenesis inhibitor epoxyquinol A: Total synthesis and inhibition of transcription factor NF-κB

Organic Letters

Volumn 4, Issue 19, 2002, Pages 3267-3270

  Li, Chaomin ^a   Bardhan, Sujata ^a   Pace, Emily A ^b   Liang, Mei Chih ^b   Gilmore, Thomas D ^b   Porco Jr , John A ^a  

^a BOSTON UNIVERSITY   (United States)

^b Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPOXIDE; EPOXYQUINOL A; HYDROQUINONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; METABOLISM; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ANGIOGENESIS INHIBITORS; CRYSTALLOGRAPHY, X-RAY; EPOXY COMPOUNDS; HYDROQUINONES; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NF-KAPPA B;

EID: 0037136468     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol026513n     Document Type: Article

References (29)

1. (a) Ryan, C. J.; Wilding, G. Drugs Aging 2000, 17, 249.
2. (b) Folkman, J.; Browder, T.; Palmblad, J. Thromb. Haemostasis 2001, 86, 23.
3. For a review of natural products as angiogenesis inhibitors, see: Paper, D. H. Planta Med. 1998, 64, 686.
4. Kakeya, H.; Onose, R.; Koshino, H.; Yoshida, A.; Kobayashi, K.; Kageyama, S.-I.; Osada, H. J. Am. Chem. Soc. 2002, 124, 3496.
5. Li, C.; Lobkovsky, E.; Porco, J. A., Jr. J. Am. Chem. Soc. 2000, 122, 10484.
6. Li, C.; Pace, E. A.; Liang, M.-C.; Lobkovsky, E.; Gilmore, T. D.; Porco, J. A., Jr. J. Am. Chem. Soc. 2001, 123, 11308.
7. Hu, Y.; Li, C.; Kulkarni, B.; Strobel, G.; Lobkovsky, E.; Torczynski, R. M.; Porco, J. A., Jr. Org. Lett. 2001, 3, 1649.
8. In refs 3 and 4, epoxyquinol and epoxyquinone dimers were referred to as "exo." However, it is more appropriate to refer to the dimers as "endo" with respect to the carbonyl substituent on the 2H-pyran dienophile.
9. 4 as catalyst afforded the undesired 1,3-diketone as the main product; cf.: Suzuki, M.; Watanabe, A.; Noyori, R. J. Am. Chem. Soc. 1980, 102, 2095.
10. Kiyooka, S.; Kuroda, H.; Shimasaki, Y. Tetrahedron Lett. 1986, 27, 3009.
11. f by TLC with the natural compound RK-302 (see Supporting Information).
12. Endo quinone dimer 9 was also produced in 67% yield by Dess-Martin periodinane oxidation of 7, followed by treatment with silica gel (Scheme 1). See Supporting Information for details.
13. It is also conceivable that internal hydride transfer of dienal 4 to a quinone epoxide may occur. For a recent example of an internal hydride transfer, see: Szendi, Z.; Forgo, P.; Tasi, G.; Böcskel, Z.; Nyerges, L.; Sweet, F. Steroids 2002, 67, 31.
14. Semmelhack, M. F.; Schmid, C. R.; Cortes, D. A.; Chou, C. S. J. Am. Chem. Soc. 1984, 106, 3374.
15. 3) analysis of the crude reaction mixture indicates a ratio of dienal 4:2H-pyran 2:dimer 1:dimer 10 of 1:4.9:7.9:7.7.
16. For enhancement of endo/exo selectivity by water in Diels-Alder reactions, see: Otto, S.; Engberts, J. B. F. N. Pure Appl. Chem. 2000, 72, 1365.
17. For endo Diels-Alder dimerization of two identical 2H-pyran monomers, see ref 4.
18. For select examples of microwave irradiation of natural products, see: (a) Salmoria, G. V.; Dall'Oglio, E. L.; Zucco, C. Synth. Commun. 1997, 29, 4335.
19. (b) Das, B.; Venkataiah, B. Synth. Commun. 1999, 29, 863.
20. (c) Das, B.; Madhusudhan, P.; Venkataiah, B. Synth. Commun. 2000, 30, 4001.
21. (d) Das, B.; Venkataiah, B.; Kashinatham, A. Tetrahedron 1999, 55, 6585.
22. 1H NMR). For a recent example of intramolecular OH-OH hydrogen bonding, see: Vasquez, T. E., Jr.; Bergset, J. M.; Fierman, M. B.; Nelson, A.; Roth, J.; Khan, S. I.; O'Leary, D. J. J. Am. Chem. Soc. 2002, 124, 2931.
23. For an example of Diels-Alder cycloaddition with π-facial selectivity anti to the diene epoxide moiety, see: Gillard, J. R.; Newlands, M. J.; Bridson, J. N.; Burnell, D. J. Can. J. Chem. 1991, 69, 1337.
24. (a) Cycloepoxydon: Gehrt, A.; Erkel, G.; Anke, T.; Sterner, O. J. Antibiot. 1998, 51, 455.
25. (b) Panepoxydon: Erkel, G.; Anke, T.; Sterner, O. Biochem. Biophys. Res. Commun. 1996, 226, 214.
26. Umezawa, K.; Ariga, A.; Matsumoto, N. Anticancer Drug Des. 2000, 15, 239.
27. For a review of natural products as modulators of the NF-κB signaling pathway, see: Bremner, P.; Heinrich, M. J. Pharm. Pharmacol. 2002, 54, 453.
28. For recent reports on suppression of angiogenesis by inhibition of NF-κB in cancer cells, see: (a) Huang, S.; Robinson, J. B.; DeGuzman, A.; Bucana, C. D.; Fidler, I. J. Cancer Res. 2000, 60, 5334.
29. (b) Huang, S.; Pettaway, C. A.; Uehara, H.; Bucana, C. D.; Fidler, I. J. Oncogene 2001, 20, 4188.